On November 3, 2016 ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, reported that new preclinical data on the Company’s novel IGN ADCs, IMGN632 and IMGN779, will be presented at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting, which is being held December 3-6, 2016 in San Diego, CA (Press release, ImmunoGen, NOV 3, 2016, View Source [SID1234516225]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
IMGN632, a CD123-targeting ADC and IMGN779, a CD33-targeting ADC, both use ImmunoGen’s new family of indolino-benzodiazepine cancer-killing agents called IGNs. ImmunoGen designed IGN payloads to alkylate DNA without crosslinking it. Data being presented at ASH (Free ASH Whitepaper) will demonstrate that DNA-alkylating IGNs are ultra-potent, yet provide increased tolerability compared with DNA crosslinking versions.
"Accelerating our earlier-stage portfolio with an emphasis on our IGN ADCs is one of ImmunoGen’s strategic priorities, and we believe the IMGN632 and IMGN779 preclinical data being presented at ASH (Free ASH Whitepaper) further demonstrate why we are excited about the potential of these programs," said Richard Gregory, Ph.D., executive vice president and chief scientific officer of ImmunoGen.
In an oral presentation, the Company will report preclinical data demonstrating the activity of IMGN632 in multiple acute myeloid leukemia (AML) models and patient samples at concentrations far below levels that affect normal bone marrow cells, suggesting the potential for efficacy in AML patients in the absence of or with limited myelosuppression. In a separate poster presentation, preclinical data for IMGN632 will be reported demonstrating prolonged survival in AML xenograft models. Preclinical data from a combination study of IMGN779 with a PARP inhibitor, demonstrating enhanced activity in several AML models including patient derived tumor cells and a disseminated AML xenograft model, will also be presented in an investigator poster presentation.
A Phase 1 trial of IMGN779 as monotherapy in AML is ongoing with the first clinical data expected to be reported in 2017. ImmunoGen intends to submit an IND application and initiate clinical testing of IMGN632 in 2017.
Oral Presentation
Title: "A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells"
Oral presentation, session #616: Monday, December 5, presentation time 11:45am PT. Abstract #768.
Poster Presentations
Title: "IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models"
Poster session #616: Sunday, December 4, 6:00-8:00pm PT. Abstract #2832.
Title: "Combining IMGN779, a Novel Anti-CD33 Antibody-Drug Conjugate (ADC), with the PARP Inhibitor, Olaparib, Results in Enhanced Anti-Tumor Activity in Preclinical Acute Myeloid Leukemia (AML) Models"
Poster session #616: Saturday, December 3, 5:30-7:30pm PT. Abstract #1645.
Data will also be presented on agents which use ImmunoGen’s maytansinoid ADC technology, including IMGN529 and Biotest’s indatuximab ravtansine (BT062).
Additional information, including abstracts, can be found at www.hematology.org.